Brief: Spago Nanomedical Preclinical Results Show Reduced Tumor Growth With TUMORAD®

Spago Nanomedical AB (publ)

25/01/2022 08:11

Jan 25 (Reuters) - Spago Nanomedical publ AB  SPAGO.ST 
    * SIGNIFICANTLY REDUCED TUMOR GROWTH WITH TUMORAD® ACCORDING
TO
NEW PRECLINICAL RESULTS

Source text for Eikon:  ID:nMFN1FW0cW 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))